FMR1 premutation carriers are at risk of developing Fragile X-associated primary ovarian insufficiency as well as Fragile X-associated tremor/ataxia syndrome. FMR1 premutation alleles are also associated with a variety of disorders, including psychiatric, developmental, and neurological problems. However, there is a major concern regarding clinical implications of smaller CGG expansions known as intermediate alleles (IA) or gray zone alleles (45-54 CGG).
| INTRODUCTION
The FMR1 gene is associated with significant morbidity. Since the description of the mutation responsible for fragile X syndrome (FXS) in 1991, we have made great progress in the knowledge of this gene and its broad spectrum of clinical implications.
The CGG expansion in the FMR1 gene was the first disease described caused by a dynamic mutation. In the general population the repeat is between 6-44 CGG, while in FXS patients it is of more than 200 CGG which is considered as a full mutation (FM). This mutation generally leads to methylation of the repeat itself and the promoter region 1 Despite population differences, according to a newborn screening in the United States, the prevalence of IA is relatively high (1/66 females and 1/112 males). 2 However, the clinical relevance of these IA alleles has been poorly studied.
Although most IA are stable, some can occasionally expand to a PM in offspring and to a FM after two or three subsequent generations. 3 IA are more prone to expansion when transmitted through males compared to females, 4 and similar to PM the risk of expansion is affected by the AGG interruptions. 5 On the other hand, using highly 
| Control population
The population based frequency of FMR1 alleles was obtained by screening of 1385 individuals (460 males and 925 females) recruited from the general population (Table 1) . Among these, we selected a subset cohort of 232 individuals above 40 years (135 males and 97 females) in order to compare IA frequency from late-onset disorders.
| Molecular analysis
DNA extraction from patients and controls was performed from peripheral blood using the Gentra Puregene blood kit (Qiagen, Hilden, Germany) or a similar standard method. Molecular analysis of the 
| Statistical analysis
Statistical analyses were performed using commercially available software (SPSS-PC, version 23.0; SPSS Inc.). The χ 2 test of frequencies and Fisher's exact test were applied to the contingency tables in order to compare IA frequencies between control and patient populations.
Significance was accepted for exact asymptotic bilateral P values < .05. Bonferroni correction was performed for multiple comparisons.
| RESULTS
The allelic and genotypic frequencies of FMR1 IA alleles are summarized in Table 2. A total of 223 patients (29 with POI, 7 with MD and 187 with NDD) and 32 controls from the general population were identified with IAs. Only one female with POI was found to be a carrier of two IA (50 and 53 CGGs).
Similar IA frequencies were detected in all the cases and controls (cases 1.20% vs controls 1.39%, P = .427). In order to adequately compare populations, the IA frequencies of the cohorts with POI and MD were compared with the entire control population and with a subset of the control population over 40 years of age. Regarding the NDD cohort, IA frequencies were compared to those detected in the whole control population. Statistical analysis did not show an excess of IA among any of the populations screened (Table 2 ). In fact, the frequency of IA carriers was significantly lower on comparing females with NDD and women in the control population (P = .02), although this difference did not reach significance on applying the Bonferroni correction for multiple comparisons.
On the other hand, a similar distribution was observed between IA harbored by cases and controls, being the most common allele (~25%) 45 CGGs in both groups ( Figure 1A) . Moreover, using regression analysis we found a negative correlation between the CGG repeat size and the number of individuals carrying a specific allele ( Figure 1B,C) . However, the coefficient of correlation was stronger in controls (R 2 = 0.90) than in cases (R 2 = 0.63).
Based on this observation, when comparing the allelic frequencies of IA ≥ 50 CGGs between cases and controls, we detected higher allelic frequencies in all the cohorts of patients (Table 3) . However, statistical analysis did not identify significant differences neither in allelic or genotypic frequencies when comparing cases and controls.
| DISCUSSION
Taking into account the high frequency of IA in the general population, it is important to determine their possible effects on different disorders.
The description of increased FMR1 mRNA levels in IA opened the debate regarding a possible clinical effect. 9 We performed a comparative analysis of the FMR1 CGG repeat locus in a large case-control study of several groups of individuals with FMR1 premutation associated pathologies. The frequency of IAs in the present study did not significantly differ from that obtained in the control population, suggesting the presence of an IA is not associated with the risk of POI, MD or NDD.
In the last years, clinical and neuropsychological involvement has been associated with individuals carrying IA. 9 To date, 5 cases of FXTAS have been described in carriers of these alleles. 10, 11 In addition, an increased prevalence of IA has been reported in children with NDD 12-14 as well as in adults with POI or Parkinson's disease (PD). [15] [16] [17] [18] [19] Nevertheless, these findings do not agree with those of other authors [eg, Refs. 8, 20, 21 ]. However, it should be taken into account that the prevalence rates are difficult to compare across studies given the variable definitions of the IA CGG repeat range.
In this study, 15626 FMR1 alleles were screened among Caucasian patients diagnosed with MD, POI and NDD, being one of the largest reported up to now. Our results suggest that IA might not confer an increased risk of developing these disorders at least in Spanish populations. These results are consistent with a previous study by our group which included a subset of NDD patients. 8 In the present study the age of the control population may be a limitation. In order to overcome this, we selected controls that were over 40 years of age to compare IA frequencies in late-onset disorders (POI and MD). Overall, we detected 2.31% of IA carriers among our Spanish control population including all males and females. This frequency did not significantly differ from that previously reported by P value (rl whole cohort) P = .90 P = .57 P = .48 --P-value (rl older cohort) P = .22 P = .16 --- P value (rl whole cohort) P = .89 P = .82 P = .02 P value (rl older cohort) P = .18 P = .34 -Males IA (%) NA 0.37% (1/272) 1.32% (163/12319) 1.52% (7/460) 1.48% (2/135) P value (rl whole cohort) -P = .27 P = .68 P value (rl older cohort) -P = .26 -Abbreviation: rl, related to.
a Exact asymptotic bilateral P values are shown.
b This cohort is a subset of the global control population recruited.
Seltzer et al 22 in 6747 controls among males and females between 67 and 78 years in the United States. These authors reported a prevalence rate of 2.6% IA with the defined range of 45 to 54 repeats. 22 Therefore, our results could be compared with this latter study.
In contrast with our results, some studies have reported an association between POI and IA. 23 However, they are not comparable with our data since the CGG repeat range used was different. 15, 16 In addition, other authors have described an increased frequency of IA in females with occult POI using the same 45 to 54 CGG repeat size as in our study. 24 Nevertheless, the association between IA and POI has not been replicated by several authors. 20, 25, 26 On the other hand, it has been reported an increased frequency of IA in patients with PD from different populations. [17] [18] [19] However, in agreement with our results a previous study by a Spanish group reported similar IA frequencies in 206 PD patients and 227 control subjects. bution. The present study showed that in the group of patients there were more larger expanded alleles compared to the control population ( Figure 1) . In fact, when considering the range between 50 to 54 CGGs, we found higher IA frequencies among females with MD and in males with ID compared to sex-matched controls (Table 3) .
However, these differences were not statistically significant, although a higher number of controls with alleles within this range would be necessary to draw conclusions regarding this subgroup of carriers.
Finally, other predisposing factors likely play an additional role in the development of the disease.
In summary, our study provides one of the largest case control studies. Based on the screening of FMR1 CGG repeats in 15 626
patients, the results of this study do not support the implication of the IA in the appearance of MD, POI or NDD considering the current range of 45-55CGGs. According to these observations, IA below 50 CGGs should not be considered as risk factors for FMR1 premutation associated phenotypes, at least in our population. However, the clinical implication of IA ≥ 50CGGs remains to be further elucidated.
Genetic counseling should undoubtedly be performed in all IA carriers in order to assess the risk of expansion in the next generations.
